Researchers have found in a new study published in Diabetes Research and Clinical Practice that prior psoriasis in patients with type 2 diabetes mellitus (T2DM) is associated with a ...

“Our study demonstrated in a large real-world population that long-term treatment of up to 5 years with adalimumab in adult patients with psoriasis led to a sustained improvement in the practice of ...

Arcutis Biotherapeutics surges on strong Q3 results, Zoryve growth, and a bullish FY 2026 outlook. Click here to find out why ...

North America and Western Europe — two wealthier regions of the world — reported the highest incidences and are projected to ...

Sun Pharma introduces Ilumya in India for treatment of moderate-to-severe plaque psoriasis: Our Bureau, Mumbai Tuesday, December 2, 2025, 14:45 Hrs [IST] Sun Pharma has announced ...

Though patients with psoriasis (PsO) or psoriatic arthritis (PsA) face an elevated risk for major adverse cardiac events (MACE), the likelihood of developing these events does not significantly differ ...

Mumbai-based Sun Pharma has introduced its global innovative biologic Ilumya (Tildrakizumab) in India for the treatment of moderate-to-seve.

A Johns Hopkins Medicine study involving a dozen people with the inflammatory skin disease hidradenitis suppurativa (HS), ...

Discover the foundation that gives a flawless, luminous look without settling into fine lines or dryness for women over 60.

Scinai Immunotherapeutics Ltd. ("Scinai", or the "Company"), a biopharmaceutical company developing innovative inflammation and immunology (I&I) therapeutics and operating a growing boutique CDMO ...

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company developing innovative ...

Mycosis fungoides is the most common subtype, making up the vast majority of CTCL cases. While early-stage disease has an estimated five-year survival rate of 88%, it remains a difficult-to-manage ...